Maravai LifeSciences Holdings, Inc. (MRVI)

8.42 +0.22 (+2.68%) 收市：04:00PM EDT

Maravai LifeSciences Holdings, Inc.

10770 Wateridge Circle
Suite 200
San Diego, CA 92121
United States
858 546 0004
https://www.maravai.com

版塊: Healthcare
行業: Biotechnology
全職員工: 650

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Carl W. Hull	Co-Founder & Executive Chairman	617.67k	無	1959
Mr. William E. Martin III	Chief Executive Officer	987.86k	無	1975
Mr. Kevin M. Herde	Executive VP & CFO	548.62k	無	1972
Dr. Peter Michael Leddy Ph.D.	Executive VP & Chief Administrative Officer	583.39k	無	1963
Ms. Christine Dolan	Executive VP & GM of Cygnus Technologies	536.63k	無	1968
Mr. Andrew Burch	President of Nucleic Acid Production	425.15k	無	1969
Ms. Debra Hart	Senior Director of Investor Relations	無	無	無
Mr. Kurt Oreshack	Executive VP, General Counsel & Secretary	701.4k	無	1981
Ms. Rebecca Buzzeo	Executive VP & Chief Commercial Officer	無	無	無
Dr. Kate E. Broderick Ph.D.	Chief Innovation Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

公司管治

截至 2024年4月29日 止，Maravai LifeSciences Holdings, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：1；董事會：10；股東權利：7；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。